Reinach, Switzerland, 25 July 2011 – Evolva Holding SA (SIX: EVE), which is developing novel medicines and nutritional ingredients through synthetic biology, announced that data on its lead drug candidate EV-077 were presented in an oral presentation today at the XXIII Congress of the International Society on Thrombosis and Haemostasis (ISTH), taking place in Kyoto, Japan. The data suggest that EV-077 might potentiate the in vivo anti-thrombotic efficacy of aspirin in type 2 diabetics with coronary artery disease. The oral presentation was delivered by Dr. Kjell Sakariassen, a prominent expert in this field and member of Evolva’s Clinical Advisory Board.
The aim of the presented study was to investigate the in vitro effect of EV-077 on platelet aggregation of patients with type 2 diabetes mellitus (DM) and coronary artery disease (CAD). The study was conducted on blood samples taken from 47 patients with type 2 DM and CAD on chronic daily treatment with 100mg aspirin.
The data demonstrate that aspirin did not completely inhibit platelet aggregation in whole blood of patients with type 2 DM and CAD. The residual aggregation could be caused by thromboxane A2 and/or isoprostanes produced by leukocytes. EV-077 almost completely abolished arachidonic acid-induced platelet aggregation in whole blood of aspirin-treated patients, suggesting it might potentiate the in vivo anti-thrombotic efficacy of aspirin in type 2 diabetics with CAD. It is estimated that between 10 million and 20 million people in the developed world suffer from this condition.
Evolva’s Chief Medical officer, Dr. Norbert Bender, said: “We are thrilled by the opportunity to share these positive data from our Phase I programme with EV-077 on this distinguished platform. The Phase I programme is now completed and we are looking forward to publishing additional data within the next few months and initiating Phase IIa later this year.”
Evolva is developing EV-077 for the treatment of complications of diabetes. EV-077 is an oral thromboxane receptor antagonist and thromboxane synthase inhibitor and belongs to a new structural class.
ISTH is the leading worldwide organisation dedicated to the advancement of understanding, prevention, diagnosis and treatment of thrombotic and bleeding disorders. It has over 3,000 members from more than 80 countries. The data were presented by Dr. Kjell Sakariassen, a long-serving member of Evolva’s Clinical Advisory Board. The title of his presentation was “EV-077-3201-2TBS, a TP antagonist and TS inhibitor, reduces platelet aggregation in whole blood of type 2 diabetics with coronary artery disease on chronic aspirin therapy”.
Dr. Sakariassen’s previous positions include Worldwide Head of Pharmacology and Early Safety Evaluation at Serono, Director and Head of Pharmacology at Pharmacia, Director and Head of Discovery Research at Nycomed, Professor of Physiology at University of Oslo and Research Scientist at Roche, Basel. He has extensive expertise in profiling Linotroban, Clopidogrel and Aspirin as well as other anti-platelet agents and anti-coagulants. He has published numerous scientific articles and is a member on scientific advisory editorial boards. Dr. Sakariassen has a Ph.D. in medical biology from University Hospital of Utrecht and is a Fellow of the American Heart Association since 2001.
Evolva is an international, innovative synthetic biology company with a world-class research platform. Evolva strives to improve people’s lives by applying its technology and other resources to the discovery and development of new products and processes that benefit the health, well-being and financial economy of patients, consumers and partner companies around the world. Evolva uses biosynthetic and evolutionary technologies to artificially create and optimise small molecule compounds and their production routes. Our approach differs from that of the mainstream in the pharmaceutical and chemical industries. We have discovery partnerships ongoing both in pharma and in nutrition. In addition we have a pipeline of promising compounds aimed at infectious and cardio-renal indications.
For more information visit www.evolva.com.
Neil Goldsmith, CEO Jakob Dynnes Hansen, CFO Paul Verbraeken, IR
firstname.lastname@example.org email@example.com firstname.lastname@example.org
+ 41 61 485 2005 + 41 61 485 2034 + 41 61 485 2035
M: Communications Mary Clark email@example.com +44 (0)20 7920 2361
This press release contains specific forward-looking statements, e.g. statements including terms like believe, assume, expect or similar expressions. Such forward-looking statements are subject to known and unknown risks, uncertainties and other factors which may result in a substantial divergence between the actual results, financial situation, development or performance of the company and those explicitly or implicitly presumed in these statements. Against the background of these uncertainties readers should not place undue reliance on forward-looking statements. The company assumes no responsibility to update forward-looking statements or to adapt them to future events or developments.